In concert to this observation, clinically, treatment of patients with idelalisib showed lowered expression of Mcl-1 protein in circulating CLL lymphocytes after 2, 4, and 12 weeks of idelalisib intake (Yang, Modi unpublished). Here, MCL1 is linked to B-cell chronic lymphocytic leukemia.